sponsored
PatientsVille.com Logo

PatientsVille

Fudr Medical Research Studies

Up-to-date List of Fudr Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Fudr Medical Research Studies

Rank Status Study
1 Recruiting Hepatic Arterial Infusion (HAI) With Floxuridine (Fudr) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
Conditions: Intrahepatic Cholangiocarcinoma;   Peripheral Cholangiocarcinoma;   Cholangiolar Carcinoma;   Cholangiocellular Carcinoma
Interventions: Drug: Floxuridine (Fudr);   Drug: dexamethasone;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Other: MRI;   Other: Research blood draws
Outcome Measures: progression free survival for Cohort 1;   progression free survival for Cohort 2;   Correlative objective of of dynamic contrast enhanced (DCE)-MRI imaging of intrahepatic cholangiocarcinoma before treatment and early during the course of treatment.;   Correlative objective of of dynamic contrast enhanced DWI of intrahepatic cholangiocarcinoma before treatment and early during the course of treatment.
2 Recruiting Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Conditions: Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: veliparib;   Drug: floxuridine;   Other: laboratory biomarker analysis
Outcome Measures: Maximum tolerated dose (MTD) defined as the dose level below the lowest dose that induces dose-limiting toxicity (DLT) in at least one-third of patients using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   Adverse events profile;   Toxicity profile assessed using CTCAE version 4.0;   Incidence of non-hematologic toxicities evaluated via the CTC standard toxicity grading;   Incidence of hematologic toxicity;   Response profile assessed using Response Evaluation Criteria in Solid Tumors (RECIST);   Time until any treatment related toxicity;   Time until treatment related grade 3+ toxicity;   Time until hematologic nadirs (white blood cell [WBC], ANC, platelets);   Time to progression;   Time to treatment failure
3 Recruiting Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma
Conditions: Cholangiocarcinoma;   Liver Neoplasms
Interventions: Drug: Floxuridine;   Drug: Dexamethasone;   Drug: Gemcitabine;   Drug: Oxaliplatin
Outcome Measures: Toxicity of HAI alone or in combination with systemic oxaliplatin and/or gemcitabine;   Time to progression;   Response rates;   Overall survival;   Number and grade of adverse events post HAI treatment;   Imaging biomarkers of tumor response
4 Recruiting Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma
Conditions: Intrahepatic Cholangiocarcinoma;   Peripheral Cholangiocarcinoma;   Cholangiolar Carcinoma;   Cholangiocellular Carcinoma) (ICC)
Interventions: Procedure: Liver resection and placement of hepatic artery infusion pump;   Drug: FLOXURIDINE;   Drug: DEXAMETHASONE;   Drug: GEMCITABINE
Outcome Measures: Safety and Toxicity;   Recurrence Free Survival
5 Recruiting Phase Ⅱ Study of Systemic Chemotherapy With/Without HAI to Treat Hepatic-only Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: mFOLFOX6;   Drug: HAI
Outcome Measures: Complete resection rate (R0 resection rate) (defined as no macroscopic or microscopic residual tumor);   Overall response rate (ORR);   Specific resection rates R0/R1/R2;   Recurrence-free Survival (RFS);   Progression free survival(PFS);   Overall survival;   Number of participants with surgical complications, AES and SAEs as a measure of Safety
6 Recruiting Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial Chemotherapy
Condition: Cholangiocellular Carcinoma
Intervention: Drug: Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin
Outcome Measure: Dose limiting toxicities (DLT) of intravenous gemcitabine with concomitant administration of Fudr-HAI and intravenous cisplatin.
7 Recruiting Trial of Preoperative Hepatic and Regional Arterial Chemotherapy (PHRAC) to Prevent Postoperative Liver Metastasis of Colorectal Cancer
Condition: Colorectal Neoplasms
Interventions: Procedure: Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and Fudr;   Procedure: surgery
Outcome Measures: 5 years disease-free survival;   5 years overall survival and liver metastasis-free survival
8 Recruiting ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis
Conditions: Appendix Cancer;   Colorectal Cancer
Interventions: Procedure: Cytoreductive Surgery;   Drug: HIPEC with Mitomycin-C;   Drug: EPIC with Fudr and Leucovorin
Outcome Measures: disease-free survival;   surgical toxicity grade 3 to 5;   chemotherapy toxicity grade 4 or 5
9 Unknown  Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver
Conditions: Colorectal Cancer;   Metastatic Cancer
Interventions: Drug: floxuridine;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
Outcome Measures: Tumor response as measured by carcinoembryonic antigen (CEA) level, RECIST criteria, and positron emission tomography (PET) scan;   Hepatic toxicity;   Therapeutic efficacy based on time from selective internal radiation therapy (SIRT) to in-liver disease progression;   Therapeutic efficacy based on the proportion of patients who achieve down-staging among all chemo-SIRT treated patients
10 Recruiting Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: panitumumab;   Drug: Randomization to No Panitumumab
Outcome Measures: to determine if panitumumab with Hepatic Arterial Infusion (HAI) in combination with systemic chemotherapy can increase the recurrence free survival (RFS) for colorectal cancer patients with resected liver metastases;   to assess toxicity as per the NCI Common Toxicity Criteria;   to determine survival;   to analyze tumor tissue for predictive biomarkers
11 Unknown  Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer
Conditions: Liver Metastasis;   Colorectal Cancer
Interventions: Procedure: TACE + folfox 4;   Procedure: TAC + folfox4
Outcome Measures: overall survival;   resection rate of liver metastasis progression-free survival
12 Unknown  Hepatic Artery Infusion With Oxaliplatin
Conditions: Colorectal Cancer;   Metastasis;   Liver Cancer
Interventions: Drug: Oxaliplatin (via HAI);   Drug: 5 Fluorouracil (systemic)
Outcome Measures: number of patients who become eligible for total resection of metastatic liver tumor;   overall survival of patients resected for cure versus (vs.) resected for palliation vs. not resected.;   toxicity;   HAI complexity;   cost
13 Recruiting Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study
Condition: Colorectal Cancer With Non Resectable Hepatic Metastasis
Intervention: Drug: HIA DEBIRI + systemic FOLFOX
Outcome Measures: Progression-free survival rate at 9 months;   safety of the study treatment;   Overall survival
14 Recruiting Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Capecitabine Plus Mitomycin
Conditions: Colorectal Cancer;   Liver Metastases
Interventions: Drug: oxaliplatin;   Drug: raltitrexed;   Drug: mitomycin C;   Drug: capecitabine
Outcome Measures: progression-free survival;   Estimate the parameters of tumor perfusion using arterial CT Scan data;   Estimate the rate of objective response according to the criteria of CHOI and RECIST;   Estimate the overall survival which will be compared with the median of overall survival in other studies published in the literature;   Estimate the rate of secondary resectable hepatic metastases;   Estimate the tolerance of the treatment (NCI-CTCAE version 4.0);   Estimate the quality of life (QLQ C30) and the fatigue MFI20
15 Unknown  Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: tac + folfox4;   Drug: folfox4
Outcome Measures: progression free survival;   overall survival
16 Unknown  A Prospective Randomized Trial Comparing Partial Hepatectomy and TACE Plus PEI for Small Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Other: operation;TACE plus PEI
Outcome Measure: overall survival

These studies may lead to new treatments and are adding insight into Fudr etiology and treatment.

A major focus of Fudr research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Fudr